1921
Volume 77, Issue 6_Suppl
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Parasite resistance to conventional antimalarial medicines has led, in recent years, to a dramatic shift in malaria treatment. Sixty-seven countries with endemic malaria, 41 of them in Africa, have recently adopted the highly effective artemisinin-based combination therapies (ACTs). In 2005, 31.3 million ACT treatment courses were procured globally for public sector use, 25.5 million of them in Africa. However, in the 39 countries, and in particular the 21 African countries in which ACTs are being deployed, access to these medicines is still unacceptably low. After a period of market instability, the global manufacturing capacity for ACTs is now sufficient to meet the demand. However, increased and sustained financing will be necessary to extend the current levels of ACT coverage. Artemisinins as monotherapies are widely available in the private sector of 47 endemic countries, and their consumption will, if unabated, promote resistance to artemisinins and compromise the effectiveness of ACTs.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2007.77.193
2007-12-01
2017-09-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/77/6_Suppl/0770193.html?itemId=/content/journals/10.4269/ajtmh.2007.77.193&mimeType=html&fmt=ahah

References

  1. WHO, 2001. Antimalarial Drug Combination Therapy. Report of a WHO Technical Consultation. Geneva: World Health Organization.
  2. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N, International Artemisinin Study Group, 2004. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363 : 9–17.
  3. White N, Olliaro P, 1996. Strategies for the prevention of anti-malarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol Today 12 : 399–401.
  4. Schapira A, Mendis KN, 2006. Strategies for global implementation of combination strategies for malaria chemotherapy. Proceedings of the 11th International Congress of Parasitology, Glasgow, Scotland.
  5. Committee on the Economics of Antimalarial Drugs: Board on Global Health IOM, of the National Academies, 2004. Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance. Washington, DC: National Academic Press.
  6. Laxminarayan R, Over M, Smith DL, 2006. Will a global subsidy of new antimalarials delay the emergence of resistance and save lives? Health Aff (Millwood) 25 : 325–336.
  7. WHO, 2005. Susceptibility of Plasmodium falciparum to Antimalarial Drugs: Report on Global Monitoring 1996–2004. Geneva: World Health Organization.
  8. WHO, 2006. Guidelines for the Treatment of Malaria. Geneva: World Health Organization.
  9. Ndyomugyenyi R, Neema S, Magnussen P, 1998. The use of formal and informal services for antenatal care and malaria treatment, in rural Uganda. Health Policy Plan 1 : 94–102.
  10. Deming MS, Gayibor A, Murphy K, Jones TS, Karsa T, 1989. Home treatment of febrile children with antimalarial drugs in Togo. Bull World Health Organ 67 : 695–700.
  11. Ruebush TK, Kern MK, Campbell CC, Oloo AJ, 1995. Self-treatment of malaria in a rural area of western Kenya. Bull World Health Organ 73 : 229–236.
  12. Brinkman U, Brinkman A, 1991. Malaria and health in Africa: The present situation and epidemiological trends. Trop Med Parasitol 42 : 204.
  13. WHO, 2003. Access to Antimalarial Medicines: Improving the Affordability and Financing of Artemisinin-Based Combination Therapies. Geneva: World Health Organization.
  14. Kirigia J, Snow R, Fox-Rushby J, Mills A, 1998. The cost of treating paediatric malaria admissions and the potential impact of insecticide-treated mosquito nets on hospital expenditure. Trop Med Int Health 3 : 145–150.
  15. Ejezie G, Ezedinachi E, Usanga E, Gemade E, Ikpatt N, Alaribe A, 1990. Malaria and its treatment in rural villages of Aboh Mbaise, Imo State Nigeria. Acta Trop 48 : 17–24.
  16. WHO, 2003. The Quality of Antimalarials. Geneva: World Health Organization.
  17. Amin AA, Snow RW, 2005. Brands, costs and registration status of antimalarial drugs in the Kenyan retail sector. Malar J 4 : 1–6.
  18. WHO, 2003. Scaling Up Home Management of Malaria: From Research to Implementation. Geneva: World Health Organization.
  19. Newton P, Proux S, Green M, Smithuis F, Rozendaal J, 2001. Fake artesunate in southeast Asia. Lancet 357 : 1948–1950.
  20. Newton P, McGready R, Fernandez F, Green MD, Sunjio M, Bruneton C, Phanouvong S, Millet P, Christopher CJM, Talisuna AO, Proux S, Christophel EM, Malenga G, Singhasivanon P, Bojang K, Kaur H, Palmer K, Day NPJ, Greenwood BM, Nosten F, White NJ, 2006. Manslaughter by fake artesunate in Asia—will Africa be next? PLos Med 3 : 752–755.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2007.77.193
Loading
/content/journals/10.4269/ajtmh.2007.77.193
Loading

Data & Media loading...

  • Received : 25 Oct 2006
  • Accepted : 07 Nov 2006

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error